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Abstract: The Asia Pacific region is an extremely diverse region, characterized by heterogeneity from a number of as-
pects, including culture, religion, economics, landscapes, and languages. This also applies to the standard of medical 
care and the regulatory requirements for approval of drugs in the region. Developed economies such as Japan and Aus-
tralia have requirements which are not dissimilar to those of the EU and USA, but still have their own unique require-
ments. The developing economies all have their own requirements. In the ASEAN region there is harmonization of the 
dossier format, but each country still has local requirements. The region has seen significant growth in clinical trial ac-
tivity, both to satisfy local registration and safety requirements and to help accelerate global trial patient recruitment. 
There is a clear need for training in all aspects of medical, regulatory, clinical and safety aspects of medicines develop-
ment, which is being addressed through several organizations and at different locations in the region. 
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1. Introduction 
he Asia Pacific (APAC) region is an extremely 
vibrant, fast moving region, characterized by 
its extreme heterogeneity from a medical, reg-
ulatory and economic perspective. The region covers a 
wide geographic area, stretching from Mongolia in the 
North to New Zealand in the South. It has diverse 
cultures, societies, economies, landscapes, climates 
and religions. Over half the world‘s population lives in 
this region with India and China being the two most 
populous countries globally. Many people still live on 
less than a dollar a day. However, due to its diversity 
the region has enjoyed remarkable economic growth 
in the last 4 decades, and could become a growth cen-
ter for the world in the coming decades
[1]
.  
The region includes both developed economies – 
South Korea, Australia, New Zealand, Taiwan, Hong 
Kong, Singapore, Japan, and developing economies – 
China, India, Vietnam, Philippines, Indonesia, Malay-
sia, Thailand, and others. There are 35 countries in the 
region, each with their own culture and language; in 
many countries such as India and China, there are 
multiple regional languages. 
Despite the rapid economic growth, there remain 
several pressing unmet medical needs. These include 
neglected diseases in the less developed parts of the 
region, an epidemic of diabetes and cardiovascular 
disease due to Westernization of diet, increases in en-
vironmentally related diseases due to rapid industrial-
ization and environmental degradation and a rapidly 
aging population putting additional strain on health 
services.
  
In addition, there are a number of diseases 
which are more prevalent in the region than in other 
parts of the world
[2,3]
. 
2. Medicines Development Overview 
From a medicines development perspective, the region 
T 
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is unique in that several countries in the region require 
specific stability data  and local clinical data in their 
own populations in order to register compounds, and 
also have mandatory requirements for post-marketing 
surveillance studies (Tables 1 and 2). This can offer 
opportunities for regional development strategies.  
All countries in the Asia-Pacific region require a 
New Drug Application (NDA) to contain sufficient 
data to support the efficacy, safety and quality of a 
pharmaceutical product before their regulatory agen-
cies can approve its marketing authorization. Many 
require a Certificate of Pharmaceutical Product (CPP) 
from the country of origin (Table 1). A key critical 
challenge is the ability to keep abreast of the often 
rapidly changing regulations, and to be able to inter-
pret the often ‗grey‘ zones in the regulations. For 
many of the developing economies, there are opportu-
nities to partner with the regulators in critical im-
provement projects, leveraging internal expertise. This 
requires depth and breadth of knowledge in the region, 
and excellent relationships with regulators.  
3. CPP and Stability Data 
However, there are certain specific considerations that 
need to be taken into consideration when preparing for 
NDA filing in countries in this region. Many APAC 
countries require that the prior marketing authoriza-
tion approval in a reference country/countries and/or 
the country of origin of a pharmaceutical product 
has been obtained, before they in turn issue their ap-
proval based on a summary review complemented by 
such a reference approval. As such, the CPP is re-
quired as part of the NDA dossier in these countries. 
Some countries will require the CPP at the time of 
submission while others can accept an initial submis-
sion dossier without a CPP and start their review 
first, but require that the CPP be furnished at a later 
period so that they can issue their approval after their 
summary review. There is little harmonization be-
tween the regulatory systems in each country. 
4. Clinical Trials 
The number of clinical trials performed in the region 
has increased steadily over the last decade, due to 
several factors. Initially global multinational compa-
nies (MNCs) recognized the region as an opportunity 
to have less costly and easier access to patients, with 
most of the strategies being driven from the US and 
Europe. The early quality issues are becoming less 
significant as more companies are carrying out clinical 
trials in the region, and native investigators with expe-
rience in the US, Australia and Europe return to the 
region. Many of the agencies are also now carrying 
out inspections, which also add to improvement in 
quality. There are also many clinical research organi-
sations (CROs) in the region driving quality and 
 
Table 1. Requirements for CPP and local clinical data in APAC countries 
NDA Requirements Group 1 Group 2 Group 3 
Reference country approval or 
CPP at time of submission 
No  Yes — Approval letter from refer- 
ence country  
Yes — CPP from reference 
country  
Local clinical data at time of sub- 
mission 
No  No  Yes  
Countries  Australia New Zealand Singapore 
(full review)  
Singapore (summary review), Malay-
sia, Thailand, Philippines, Indonesia, 
Hong Kong  
China, Korea, Taiwan, India, 
Japan 
 
Table 2. Requirements for local clinical data 
Local Data  
Requirements 
China Korea Taiwan Japan India 
Local Ph I/ PK re-
quirements  
Yes — local PK and it 
may be conducted in 
parallel with Ph III study  
Phase I – 20 subjects  
Not required  Not required  
If bridging study evaluation 
(BSE) accepted  
Yes, and may be conducted  
In parallel with Phase II/III  
Not required  
Local subject number 
in Phase III  
Per regulations:  
Ph III — 100 (small 
molecules) and 300 (bio-
logics) in active arm + 
statistical significance  
30 to 50 in 
active arm 
(in practice)  
Per regulations:  
If total n > 200, 5% or 30 
whichever is lower,  
If total n < 200, 10% or 10 
whichever is lower  
Negotiable 100 in total  
PMS Usually Yes No Yes Yes 
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Figure 1. Current numbers of clinical trials on clinicaltrials.gov[4], viewed June 2, 2016. 
 
standardization. The growth in Asia Pacific is rapidly 
changing the strategic focus and many MNCs include 
the regional input at an early stage in development. 
There are also many emerging Asian bio-pharmac-
eutical companies who are developing products for 
commercialization on the global arena. The diseases 
prevalent or more common in Asia, such as hepato-
cellular carcinoma, gastric cancer, dengue fever and 
others, are driving innovation. Biomedical R&D ex-
penditure has increased in the region compared to that 
of US and Europe, driven primarily by Japan and 
China
[2]
. 
Clinical data submitted to support efficacy and sa-
fety of the pharmaceutical product should be generat-
ed from well-designed trials conducted in accordance 
to Good Clinical Practice (GCP). They should be ro-
bust enough to stand up to reviews by well-established 
regulatory agencies such as the US Food and Drug 
Administration (FDA) and the European Medicines 
Agency (EMA). Key agencies in the region, such as 
the Pharmaceuticals and Medical Devices Agency 
(PMDA) in Japan, the Health Sciences Authority 
(HSA) in Singapore
[5]
 and the Therapeutic Goods 
Administration (TGA) in Australia have links and 
communicate frequently with each other and with 
FDA and EMA. These agencies also provide training 
for other agencies in the region. In some cases, bridg-
ing studies performed locally can fulfil the require-
ment for local data, or participation in a global trial 
may also suffice, if the subject numbers are sufficient.  
5. Region/Country Overviews 
In the ASEAN region — Singapore, Malaysia, Thai-
land, Vietnam, Brunei, Myanmar, Philippines, Cam-
bodia, Laos, Indonesia — much work is ongoing to 
harmonize requirements and regulations. Most coun-
tries have adopted the ASEAN Common Technical 
Document (CTD) for submissions. The ASEAN CTD 
is similar in format to the ICH CTD, with local modi-
fications. There are now no requirements for local 
clinical data for registration or for post marketing sur-
veillance studies for New Chemical Entities (NCEs). 
Until recently, Vietnam required the collection and 
submission of local data for compounds which had not 
already been on the market for 5 years outside Vi-
etnam, but this requirement has recently been removed 
for small molecules. The ASEAN region also has spe-
cific Zone IV (Hot humid/tropical zone) stability re-
quirements. 
India has updated its regulations recently, following 
accusations that there were many clinical trials being 
conducted in India without adequate protection for 
subjects. The new regulations mandate fixed compen-
sation according to a specific formula, review of tri-
als by the Drug Controller General of India (DCGI), 
and video taping of subject consent for specific vul-
nerable populations. Initially almost all trials in India 
stopped while the regulations were being updated, but 
in the last year the number of companies conducting 
clinical studies in India has increased (Figure 2).  
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Figure 2. Clinical trial approvals in India 2009–2015[6].  
 
 
 
 
Figure 3. Number of clinical trials registered in the Clinical Trials Registry — India (CTRI) (includes all trials).  
 
There are excellent centres with investigators experi-
enced in conducting trials. The ministry is also taking 
steps to accredit and register clinical trial centers
[6]
. 
Currently China is possibly the toughest regulatory 
environment, with imported NCEs taking up to 6 
years for registration. The number of submissions 
(Figure 4) is very large compared to other agencies, 
driven mostly by generic submissions. Local clinical 
trials to collect local data are required for imported 
drugs, and the backlog of applications for Clinical 
Trial Permissions due to the high volume and relative 
under-staffing at the China Food and Drug Admin-
istration (CFDA) is proving frustrating for many 
companies. The CFDA recently released guidelines 
for the conduct of multi region clinical trials (MRCT) 
with at least three countries including China, for un-
met medical needs and life threatening disease, which 
may help to speed up registrations. A new guidance 
was issued recently. This describes (i) launching a 
pilot program of a market authorization holder (MAH) 
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Figure 4. Annual drug submissions received by CFDA  
TCM: Traditional Chinese Medicines 
 
system for drugs, where the market authorization 
holder may be the marketing organization not just a 
manufacturing site, (ii) allowing synchronous in-cou-
ntry clinical trials for new drugs that have not yet been 
marketed overseas, and (iii) adopting qualified clinical 
data obtained directly from multicenter clinical trials. 
Four sites in Taiwan have also been qualified so that 
their data can be used in China. 
Since July 2015, the CFDA has been conducting 
inspections on clinical trials and clinical trial sites in 
China, with the aim of improving the quality of clini-
cal trial data. This has led to additional delays, cou-
pled with the requirement since October 2015 for re-
view and approval by the Human Genetic Resource 
Authority, which is adding 3–6 months to timelines. 
Another new guidance was recently released with 
the objective of clearing the backlog of applications 
waiting for review.  Drugs with significant clinical 
value will be given priority, including those for AIDS, 
hepatitis, rare diseases, cancer and pediatric popula-
tions. The classification of drugs has changed to a new 
definition for ―new‖ drugs. Other measures include 
increasing significantly the registration fee for appli-
cations, and recruiting 300 new staff members to sup-
port reviews. The backlog was reduced from 23,000 to 
17,275 by end 2015
[7]
.
 
Overall, the reforms emphasize improving the effi-
ciency of the review system, resolving the drug appli-
cation backlog by the end of 2016, improving the 
quality of generic drugs, improving the quality of 
clinical trials, encouraging the development of inno-
vative drugs and creating a more transparent review 
and approval process
[8]
. 
Many multinational companies have opened R&D 
centers in China, in order to capitalize on the wealth of 
talent and the opportunities in the region. It has been 
suggested that China has over the next 10 years 
will become a major force in global pharma
[9]
. 
Japan has required local data for many years, and 
has moved from requiring repeat of the entire devel-
opment program in Japan to now being open to mul-
ti-region or global trials including Japanese patients, 
provided the number of Japanese patients is sufficient 
to meet the Japanese regulatory requirements. Japan is 
routinely included in global development trials by 
many MNCs. Last year, the Pharmaceutical Affairs 
Law was revised in order to strengthen safety of drugs 
and device registration
[10]
. It is now the third largest 
market in the world, after the US and China, and so 
remains very attractive
[11]
. 
Taiwan requires local data or a bridging study 
which may include Asian patients or provide pharma-
cokinetic justification, which is the path most com-
monly used. Taiwan is an increasing center for clinical 
trials in the region, given the short timelines for ob-
taining regulatory and ethics approval, and the high 
quality of data from experienced clinical trial cen-
tres
[12]
. Four centers have also been approved for use 
of the data to submit for inclusion in NDAs for Chi-
na
[13]
. 
South Korea is also a major center in the region for 
clinical trials, due to the regulatory, political and de-
mographic favorable conditions. The government has 
established clinical trial training centers, improved 
and streamlined the clinical trial approval process 
within the regulatory framework. The quality of trials, 
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ease of the regulatory framework and medical infra-
structure, along with the requirements for local data 
for product registration, have attracted many MCNs to 
do trials in Korea. Clinical trial data generated in 
South Korea can be accepted in Japan, which allows 
an Asian strategy for product development
[14–16]
. 
In Australia, current data suggests that around 1000 
new clinical trials are commenced in Australia each 
year by pharmaceutical, biotechnology and medical 
device companies, representing a $1 billion investment, 
the top 10 global pharmaceutical companies being 
responsible for 20% of this investment
[17]
. There 
has been a shift in trend in the type of clinical trial ac-
tivity conducted in Australia. Historically, Phase III 
studies have dominated. However, since 2008, there 
has also been a significant increase in early-phase ac-
tivity, reflecting global trends, along with local capa-
bilities in early-phase clinical research. 
Australia boasts a quality medical research infra-
structure and a skilled workforce, a world-class hea-
lthcare system, a stable socio-economic environment, 
an ethnically diverse population and a strong intellec-
tual property regime. An efficient regulatory system, 
including a rapid clinical trials approval system, its 
proximity to Asia, a strong mechanism of support ser-
vices, streamlined processes and globally competitive 
tax incentives for research and development (R&D) 
investment, all contribute to making it attractive for 
conducting trials
[18]
. 
The TGA is responsible for the regulation of medi-
cines and medical devices in Australia. In December 
2011 a comprehensive package of TGA reforms, 
drawn together by the Australian Government, were 
announced in the TGA reforms: A blueprint for the 
TGA’s future. The blueprint reforms aim to improve 
community understanding of the TGA‘s regulatory 
processes and decisions, enhance public trust and con-
fidence in the safety and quality of therapeutic goods. 
A four-year implementation plan was put into place, 
focusing on the areas of communication and stake-
holder engagement, advertising of therapeutic prod-
ucts, complementary medicines (or traditional and 
alternative medicines), medical devices and promotion 
of therapeutic products
[19]
. 
There is a national focus on continuous improve-
ment of the industry through government reform and 
policy innovation. Two significant examples are the 
Therapeutic Goods Administration (TGA) reforms and 
the Australian Government Clinical Trials Initiatives
[20]
. 
The Australian Government, in partnership with in-
dustry and other stakeholders, is currently undertaking 
initiatives (Australian Government Clinical Trials Ini-
tiatives) to improve the clinical trials environment in 
Australia, whilst maintaining the highest quality and 
ethical standards. These include a focus on reducing 
study start-up times, working towards a nationally 
consistent approach to clinical trials, boosting patient 
recruitment and developing a standard list of costs for 
clinical trials
[20]
. 
6. Post-marketing Surveillance (PMS) 
Japan, Korea, India and China have specific require-
ments for PMS studies in order to collect data for li-
cense renewals. There are specific requirements and 
guidelines from each country regarding number of 
patients, length of study, study design, etc. The data 
should be submitted as part of the license renewal ap-
plication
[21]
. 
7. Strategic Development Options 
Given the number of countries requiring local data for 
registration, there are several strategic options in the 
region to obtain approval. These include stand-alone 
trials in each country, inclusion of the countries into 
global trials, and regional multi-country trials. The 
region is also increasingly being included to achieve 
recruitment numbers for global trials, in Australia for 
example, even if local data is not required. The ad-
vantages of having experienced investigators and local 
data which can be leveraged for publications and re-
imbursement are not to be underestimated. The best 
option will depend on the individual compound, the 
number of patients to be recruited and the timelines 
to be met.  
8. Education 
It is critical to have well trained staff who are able to 
manage the complexities in the region. Regulatory 
affairs, drug safety, medical and clinical affairs staff 
all need to be informed and abreast of the changing 
environment and are able to have the knowledge base 
and critical and strategic thinking skills to leverage. 
There are a number of ongoing activities aimed at 
advancing education in pharmaceutical medicine in 
the region. There are courses already available in Bei-
jing, China, Osaka, Japan and at the University of New 
South Wales, Sydney, Australia
[22]
. Education of this 
kind is a critical need to keep pace with the growth in 
the industry, and in particular the growth in clinical 
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trials and medical affairs activities, needing experi-
enced, well-trained personnel.  
9. Conclusion 
The region is fast moving with a constantly changing 
environment, with many countries taking steps to im-
prove their healthcare, including strengthening regis-
tration and safety requirements. The opportunities 
abound, and this is being increasing recognized by 
MNCs who are focusing their efforts and setting up 
regional offices and R&D centers in the region. There 
are new regulations, new guidance and changes in the 
regulations happening continuously. It is therefore 
critical to have experienced people on the ground that 
keep abreast of the changes and provide key inputs as 
required to leverage the knowledge base and experi-
ence of MNCs and local companies. With this in place, 
it will be possible to leverage the possibilities and   
help shape the environment in order to bring much 
needed therapies to patients in the region
[23]
. 
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